The invention describes formulations that include either metformin,
sulfonylurea or a biguanide-sulfonylurea combination as one active
ingredient in addition to specific, other active ingredients. The
compositions and dosage forms of the invention are clinically useful as
methods for increasing the effectiveness, efficiency and safety of the
included biguanide (metformin) and/or sulfonylurea in the prevention and
treatment of insulin resistance and diabetes mellitus. The carefully
chosen additional active ingredients of the invention are designed in a
modular fashion to prevent and rectify adverse events associated with
insulin resistance syndrome and diabetes mellitus, and those adverse
incidences associated with the concurrent use of metformin and/or the
sulfonylureas. When clinically administered, the invention will provide
therapeutic levels of metformin and of a sulfonylurea, alone or in
combination, and broaden their usefulness. The invention will retard the
progression of insulin resistance to type 2 diabetes, and reduce the
serious microvascular and macrovascular complications commonly associated
with insulin resistance syndrome and diabetes mellitus.
